CTLT | Jotup

Catalent Stockholders Approve Transaction with Novo Holdings

Retrieved on:

星期三, 五月 29, 2024

Biotechnology, Pharmaceutical, Health, Security (finance), Certification, Patient, Calendar, Novo, Special, CTLT, Novo Holdings A/S, CDMO

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”).

Key Points:

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”).
“Today’s outcome represents an important milestone towards the closing of this transaction, and we thank our stockholders for their overwhelming support and their confidence in the future of Catalent,” said Alessandro Maselli, President and Chief Executive Officer of Catalent.
“Following the closing of the transaction, we look forward to writing the next chapter for Catalent, benefiting from Novo Holdings’ expertise and resources as we continue to be a global leading independent CDMO, developing, manufacturing and supplying products that help people live better and healthier lives.”
Based on the preliminary count of the voting results from today’s Special Meeting, Catalent stockholders voted to approve the transaction with 99.2% of ballots cast in favor of the proposed transaction.
The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals.

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

Retrieved on:

星期三, 五月 8, 2024

Biotechnology, Pharmaceutical, Health, CTLT, Biopharmaceutical, GAAP, Novo Holdings A/S, Patient, Calendar, Growth, Pharma

Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.

Key Points:

Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.
“I am pleased to report that in the fiscal third quarter Catalent returned to growth, including double-digit non-COVID year-on-year revenue growth.
Additionally, we achieved record third quarter non-COVID customer wins, and our non-COVID customer wins in the first three quarters of the fiscal year increased double digits over the prior year.
Third quarter fiscal 2024 Adjusted EBITDA(1) was $163 million, or 15.1% of net revenue, compared to $105 million, or 10.1% of net revenue, in the third quarter a year ago.

Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings

Retrieved on:

星期四, 四月 11, 2024

Steps, CTLT, Catalent, Novo Nordisk Foundation, Acquisition, News, SAN

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. (NYSE: CTLT) by Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation.

Key Points:

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. (NYSE: CTLT) by Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation.
Under the terms of the agreement, Catalent stockholders will receive $63.50 in cash for each share of Catalent common stock owned.
On February 2, 2024, the companies announced a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion.
Robbins LLP is concerned that Catalent's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)

Retrieved on:

星期四, 四月 18, 2024

Class Action Lawsuit, Professional Services, Legal, Steps, CTLT, Acquisition, Catalent, Novo Nordisk Foundation, News

Under the terms of the agreement, Catalent stockholders will receive $63.50 in cash for each share of Catalent common stock owned.

Key Points:

Under the terms of the agreement, Catalent stockholders will receive $63.50 in cash for each share of Catalent common stock owned.
Is the Proposed Acquisition Best for Catalent, Inc. (CTLT) and its Shareholders?
According to the news release, Catalent's board of directors approved the merger agreement for $63.50 per share in cash.
Robbins LLP is concerned that Catalent's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG

Retrieved on:

星期四, 四月 4, 2024

Empire, NuStar Energy, SCX, Everbridge, Sale, Catalent, CTLT, Thoma Bravo, NS, Security (finance)

Under the terms of the agreement, NS shareholders are expected to receive 0.4 shares of Sunoco per share they own.

Key Points:

Under the terms of the agreement, NS shareholders are expected to receive 0.4 shares of Sunoco per share they own.
Under the terms of the agreement, CTLT shareholders will receive $63.50 in cash per share they own.
Under the terms of the agreement, EVBG shareholders will receive $28.60 in cash per share they own.
Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court?

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

Retrieved on:

星期四, 三月 7, 2024

Pomerantz, FDA, News, Syringe, Novo Nordisk, Safety, Food and Drug Administration, LLP, Catalent, Freedom, CTLT

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).

Key Points:

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).
The investigation concerns whether Catalent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
As part of the transaction, Novo Nordisk will acquire three Catalent manufacturing facilities, including a plant located in Bloomington, Indiana.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Catalent, Inc. by Novo Holdings

Retrieved on:

星期五, 三月 1, 2024

Acquisition, Person, Telephone, Sale, Novo Nordisk, LLP, Catalent, CTLT, Holding company

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Catalent by Novo Holdings (“Novo”).

Key Points:

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Catalent by Novo Holdings (“Novo”).
As a result of the merger, Catalent stockholders will receive $63.50 per share in cash.
Novo is affiliated with Novo Nordisk, and Catalent is the main manufacturing partner for Novo Nordisk’s blockbuster weight loss drug, Wegovy.
Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

Retrieved on:

星期三, 二月 28, 2024

Pomerantz, FDA, News, Syringe, Novo Nordisk, Safety, Food and Drug Administration, LLP, Catalent, Freedom, CTLT

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).

Key Points:

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).
The investigation concerns whether Catalent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
As part of the transaction, Novo Nordisk will acquire three Catalent manufacturing facilities, including a plant located in Bloomington, Indiana.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

Retrieved on:

星期四, 三月 7, 2024

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community.

Key Points:

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community.
The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.
One area of significant progress in fiscal 2023 was Catalent’s efforts to reduce its environmental footprint and address the harmful effects of climate change.
A key initiative supporting this progress was the implementation of ISO-certified environmental management systems at 24 Catalent locations, which account for more than 70% of Catalent’s overall energy use.

CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT

Retrieved on:

星期五, 二月 16, 2024

Class Action Lawsuit, Professional Services, Legal, KSF, Catalent, Sale, CTLT

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings.

Key Points:

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings.
Under the terms of the proposed transaction, shareholders of Catalent will receive $63.50 in cash for each share of Catalent that they own.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .